Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies

TransinsightAbcam, a bioscience company specialising in the supply of antibodies from a web-based catalogue and Transinsight, a specialist in semantic search technologies announced a collaboration in the field of protein information quality control using bioinformatics workflows.

Accurately compiling all the required information around antibody targets is a challenging task, which has created the requirement for an automated intelligent computer-based solution to ensure top-quality information content about proteins. For example, an average human gene name has 6 or 7 synonyms and many more spelling variants. Hand-curated databases do not cover all possible ways of naming and spelling genes and hand-curation is a tedious, error prone and labour-intensive task.

"Until recently there were only limited software tools and scientific workflows available to help us automatically produce high quality data sets surrounding each of Abcam’s thousands of antibody targets. We need these data sets to help our customers find the right products", says Dr. Harter, Senior Business Development Manager at Abcam. Harter continues "We were looking for solutions for supporting our team of experts and were impressed by the advanced technologies of Transinsight. The fact that the company operates the semantic search engine GoPubMed.org and has extensive bioinformatics and protein databases expertise made the decision to work with Transinsight easy."

The award winning technology behind GoPubMed fully automates very difficult analyses normally done by scientists with equal or better performance, predicting the necessary information by sophisticated algorithms. "It is good to see how we can significantly enhance our customers' performance by improving their data quality and thus freeing their staff from an unnecessary burden" says Michael R. Alvers, CEO at Transinsight.

Related news articles:

About Abcam
Abcam plc is a producer and distributor of research-grade antibodies and associated products headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japan office located in Tokyo. The Company produces and distributes its own and third party produced antibodies to academic and commercial customers throughout the world with product information and ordering available through the Company’s website, www.abcam.com. Abcam’s vision is to build the largest online catalogue of the best antibodies in the world.

About Transinsight
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honoured with international awards. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, StatoilHydro, Wintershall, Abcam and EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

Most Popular Now

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

A Novel AI-Based Method Reveals How Cell…

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous...